Nautilus Biotech S.A. Sustainability Profile
Nautilus Biotech S.A., headquartered in France, is a pioneering company in the biotechnology sector, specialising in the development of innovative protein-based therapeutics. Founded in 2015, Nautilus has rapidly established itself as a leader in the biopharmaceutical industry, focusing on advanced drug discovery and development processes that leverage cutting-edge technologies. With a strong presence in Europe and expanding operations globally, Nautilus Biotech is renowned for its unique approach to protein engineering, which enhances the efficacy and safety of therapeutic proteins. The company’s core offerings include bespoke protein design and optimisation services, setting it apart in a competitive market. Nautilus has achieved significant milestones, including strategic partnerships and successful product launches, solidifying its position as a key player in the biotechnology landscape.
DitchCarbon Score
How does Nautilus Biotech S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nautilus Biotech S.A.'s score of 26 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nautilus Biotech S.A.'s reported carbon emissions
Nautilus Biotech S.A., headquartered in France, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Nautilus Biotech may be in the early stages of developing its climate strategy or may not yet have established formal commitments to reduce its carbon footprint. In the context of the biotechnology industry, companies are increasingly recognising the importance of sustainability and climate action. As such, Nautilus Biotech may benefit from aligning with industry standards and frameworks, such as the Science Based Targets initiative (SBTi), to set measurable and ambitious climate goals in the future.
How Carbon Intensive is Nautilus Biotech S.A.'s Industry?
How Carbon Intensive is Nautilus Biotech S.A.'s Location?
Nautilus Biotech S.A.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Nautilus Biotech S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
